As the Ways and Means Committee finished the work of amending the House tax reform bill, Chairman Kevin Brady (R-Texas) stated that efforts are already underway to begin consideration of legislation to address key Patient Protection and Affordable Care Act (ACA) taxes that are set to go into effect in 2018. This includes both the job-killing medical device tax and health insurance tax. In a statement, Chairman Brady promised, “we will move to these important health policies separately and immediately after conclusion of our tax reform efforts.” To read the full statement, click here. Read More
The Senate returned from its August recess, and health care concerns continue to loom. The Senate Health, Education, Labor and Pensions (HELP) Committee kicked off a series of hearings exploring weaknesses of the individual insurance market that have developed as a result of the Affordable Care Act (ACA). Because a legislative effort to repeal and replace the ACA failed in the Senate in July, these hearings signal a fresh start and a bipartisan approach to building consensus on health care reform. Read More
This morning, the Senate is voting on H.R. 2430, the Food and Drug Administration Reauthorization Act of 2017 (FDARA), hopefully with the affirmative action of sending the bill to President Donald Trump’s desk. The bill was passed by the House of Representatives with overwhelming bipartisan support in July.
As noted in a National Association of Manufacturers’ letter to the Senate, “FDARA is the ultimate public–private partnership that supports patients who need lifesaving medical treatments while promoting science, research and technological innovation.”
Manufacturers in America lead the nation in research and development (R&D), driving more innovation than any other sector. Pharmaceutical manufacturers, in particular, account for nearly one-third of all manufacturing R&D. In turn, the United States is a global leader in the development of medical breakthroughs.
Reauthorization of the FDA’s user-fee program would support the research pipeline and accelerate the development of new medicines and treatments. The NAM supports the Senate’s effort to act quickly in voting to reauthorize FDARA as it stands before adjourning for recess. Any delay to this critical legislation would jeopardize America’s position as a global leader in medical discovery.
During the current debate on legislation to repeal Obamacare, the Senate may have the opportunity to vote on a provision—introduced by Sen. Al Franken (D-MN)—that would eliminate the ability of companies to deduct advertising and promotional expenses related to prescription drugs. This is a misguided idea, and we urge senators to reject this proposal. Long recognized as a legitimate and necessary business expense, advertising plays a critical role in the competitiveness of manufacturers and the success of their products. Advertising plays a central role in driving market growth and innovation, which benefits both the manufacturer and the consumer. In doing so, advertising also helps drive prices down by spurring competition. In contrast, disallowing a deduction for direct-to-consumer advertising of prescription drugs increases the costs to pharmaceutical companies by denying a legitimate business expense and also unfairly targets a specific industry for discriminatory tax treatment.
Today, the House is considering positive legislation allowing small employers the flexibility to offer pretax dollars to help pay premiums and/or other out-of-pocket costs associated with medical care and services. The Small Business Health Care Relief Act (H.R. 5447), sponsored by Reps. Charles Boustany (R-LA) and Mike Thompson (D-CA), allows employers with fewer than 50 employees to provide Health Reimbursement Arrangements (HRAs) to employees with health insurance.
Effective July 1, 2015, an IRS guidance placed a $100-per-day, per-employee penalty for employers that fail to offer a group health plan but provide tax-preferred dollars through an HRA for their workers to pay health insurance premiums or other direct medical expenses. The Small Business Health Care Relief Act allows small businesses—that are not required by the Affordable Care Act to provide health insurance—to provide some assistance to their employees and provide these HRAs. This simple, logical and bipartisan change will increase coverage, improve flexibility and promote wellness for manufacturers and other small employers.
The NAM recently signed onto a letter encouraging passage of this legislation in the House, and we urge action in the Senate.
Nearly half of all Americans receive health insurance benefits from an employer. And manufacturers in particular take great pride in offering health coverage to their employees—ninety-seven percent of NAM members provide health insurance to their workers and families. It’s not only a matter of doing the right thing; it’s also about keeping employees healthy and productive in a globally competitive economy. Furthermore, employees are grateful for the benefits provided to them. A 2015 Employee Benefit Research Institute (EBRI) study found that only 9 percent of employees were unsatisfied with their health care plans.
Since World War II, employers have been actively engaged in providing health care to their employees. First as basic coverage, but today that has grown into coverage for vison and dental plans, wellness and even on-site clinics. Despite the mandates, additional regulation and taxes imposed on employers as a result of the Affordable Care Act (ACA), manufacturers are proud to provide health care, and many work against the odds to continue to do so. Read More
Last week, National Association of Manufacturers’ Robyn Boerstling sat down to talk RealClearHealth’s Karl Eisenhower about manufacturers’ needs and concerns with healthcare. Boerstling, highlighted in the video below, addresses the changing environment and employers need to “band together” by sharing data and experiences. She also describes changes to the ACA manufacturers would like to see in 2016 and discusses the opportunities for reform in the first 100 days of a new administration.
To learn more, check out the interview on RealClearPolitics.
Yesterday, Robyn Boerstling, vice president of infrastructure, innovation and human resources policy for the National Association of Manufacturers, recently sat down with RealClearHealth’s Karl Eisenhower to talk about key health care issues facing manufacturers. In a two-part video series, this clips highlights manufacturers’ concerns about the “Cadillac” tax, rising health care costs and how the Affordable Care Act impacts manufacturers.
To learn more, check out the interview on RealClearPolitics.
NAM President and CEO Jay Timmons and the NAM team stopped in Philadelphia, Pa., on the fourth day of the State of Manufacturing Tour. On a day focused on innovation and changing perceptions on manufacturing, Timmons gave his address at the state-of-the-art GlaxoSmithKline (GSK) facility in Philadelphia.
At the event, co-hosted by The Pennsylvania Manufacturers’ Association (PMA) and GSK, health care and innovation were at the center of the conversation. Timmons was joined by David N. Taylor, PMA president, and Jack Bailey, GSK president of U.S. pharmaceuticals, two manufacturing champions.
Highlights from the address on health care:
“It’s an issue that has become so riven by political discord, we are losing sight of our end goal…giving workers and families affordable access to high-quality health care to keep them well. This is something the NAM cares deeply about. NAM members offer employee health insurance coverage at a higher rate than other industries. In fact, 97 percent of companies supply it. Now part of the challenge is making sure we prescribe the right medicine for health care. Here at GlaxoSmithKline, you understand matching the intervention to the patient. When treatments rely on our own genes to spark the right immunological response…well, it doesn’t get more individualized than that. Personalized treatment is the trend in medicine. On the policy front, however, there’s some movement in the opposite direction—away from the individually tailored and toward the one size fits all.”
Highlights from the address on innovation:
“Manufacturers account for more than three-fourths of private-sector R&D. We’ve been awarded more patents than any other industry. To secure our competititiveness, we must respond with a policy environment designed to attract and retain investment…and with strong protections of intellectual property.
“We must be vigilant and push back on aggressive state legislatures that want to require pharmaceutical manufacturers to turn over and reveal highly sensitive operational information—such as pricing on specific products, marketing costs, research investments and funding streams that support new product development. It’s a misguided effort that will sap innovation, and it’s of great concern. No manufacturer should have to provide an unprecedented view of proprietary operations or its most sensitive information.
“Manufacturers will not accept this, nor will we sit quietly. Intellectual property rights must also be a central issue in trade agreements. As we work to open new markets, we cannot allow our hard-won innovations to be appropriated by our competitors. And as we champion the Internet of Things, we’ll need to modernize our communications laws to fit this new era and find new ways for ensuring our cybersecurity.”
To read the full address, check out the President’s Blog.
Timmons and the team also toured the Philadelphia Distillery and spoke with employees about the challenges of being a small manufacturer and what they want to see from Washington.
Highlights from the tour:
U.S. Rep. Pat Meehan, who represents Pennslyvania’s 7th District, sent us a video since he is in Washington, D.C., for votes and work. Rep. Meehan discusses how manufacturers in Pennsylvania are thriving.
“If you feel like the health-care debate has grown stale, know you’re not alone. Despite the many presidential candidates vying to lead this nation, we are hearing little new on the topic. Vitriol and political discord continue to bar us from identifying solutions to control costs, fuel innovation, preserve the employer-based health-care system and take care of workers and their families.
“This matters to Pennsylvania, where health care is an issue not just for families but also for manufacturing. As a home to many pharmaceutical leaders and medical-technology innovators, the Keystone State is on the leading edge of medical manufacturing.”
To read the full op-ed, check it out here.
Social Media Wrap on Philadelphia:
We came to Philadelphia with big expectations, and the City of Brotherly Love did not disappoint. Check out the highlights from our social media efforts and don’t forget to follow @shopfloorNAM on Twitter and Shopfloor on Facebook for the latest updates from the road.
Don’t forget ShopFloor is on Instagram with daily updates from the NAM’s Erin Streeter. Follow us @shopfloorNAM.
And the NAM is on Vine with a behind-the-scenes look at the tour.
Want to keep in touch with the NAM as we continue on the 2016 State of Manufacturing Tour? Follow us on Facebook, Twitter @shopfloorNAM and online at www.nam.org/stateofmfg and share your tweets and pics with #StateofMFG and #WeAreMFG.
Over the past several weeks, I’ve been writing about measures in several states that are looking to impose greater reporting burdens on one particular segment of the manufacturing sector in the name of greater transparency. One provision of the so-called transparency measures being debated in several state houses around the country would require manufacturers of medicines to report the prices they charge in other countries for their products. While on the surface this may seem like a useful exercise, in reality, it is completely irrelevant to consumers. The price of medicine in one country or another should have no more bearing on what the price should be in the United States than a similar comparison of the price of ball bearings in Bangladesh or Boston. The point is, they are completely different markets, and countries often differ dramatically in their approach to the delivery of health care to the degree that any comparison is meaningless.